OVERVIEW

 

 

NEUROTECH INTERNATIONAL LIMITED, OR NEUROTECH, IS FOCUSED ON FACILITATING THE DEVELOPMENT AND COMMERCIALISATION OF SOLUTIONS FOR THE SCREENING AND TREATMENT OF SYMPTOMS ASSOCIATED WITH NEUROLOGICAL CONDITIONS SUCH AS AUTISM.  THE COMPANY INCORPORATED IN AUSTRALIA, OPERATING THROUGH ITS WHOLLY-OWNED, MALTA-BASED SUBSIDIARY, AAT RESEARCH LIMITED.

 

Our primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions which are accessible and affordable. Through Neurotech commencement of the world’s first study to assess full spectrum medicinal cannabis naturally containing <0.3% THC in children with Autism Spectrum Disorder (ASD), and our medical device, Mente Autism, and the associated software platform.

Neurotech is focused on the development and commercialisation of technological solutions for the diagnosis and treatment of such conditions, starting with autism. The development of the Mente Autism headband, now in its third iteration, represents years of research, testing and pilot studies, to effectively bring a highly specialised treatment for the management of autism, from the hospitals and clinics, into the comfort and familiarity of a patient’s home. In doing so, Neurotech and the Mente technology sit at the confluence of several market forces, including a heightened focus on understanding the brain, the increasing diagnosis of neurological conditions and the increasing adoption of home-based precision healthcare.